Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose: A Randomized,Double-Blind, Placebo-Controlled Phase 1b/2 Study
摘要: Objective Recaticimab(SHR-1209) significantly reduces low-density lipoprotein cholesterol levels.However, its effect on glucose metabolism remains unclear. This study aimed to evaluate its e... ...
(共9頁(yè))
開(kāi)通會(huì)員,享受整站包年服務(wù)